Operator: Thank you for standing by. This is the conference operator. Welcome to the Biora Therapeutics Fourth Quarter 2022 Financial Results Conference Call.
Patients with inflammatory bowel disease who had three or four specific acetyltransferases in their gut microbiota had a threefold higher risk for 5-ASA treatment failure.